Literature DB >> 12472487

Modulating diseased skin with tissue engineering: actinic purpura treated with Apligraf.

Meggan N Banta1, Robert S Kirsner.   

Abstract

BACKGROUND: Actinic purpura (AP) is an important medical issue and quality of life issue in the elderly. Current treatment of AP is limited to prevention of cutaneous aging.
OBJECTIVE: To assess the utility of tissue engineered skin (Apligraf, Organogenesis, Canton, MA) as a tissue modulator in diseased skin and as treatment for AP.
METHODS: A thin partial-thickness section of AP was removed from the forearm of an elderly gentleman and replaced with fenestrated Apligraf. Healing, durability and cosmetic outcome were assessed.
RESULTS: Apligraf-treated skin healed rapidly with good clinical "take." Lack of new skin tears and resultant erosions or ulcer formation suggests improved durability of the Apligraf-treated area occurred.
CONCLUSION: These results suggest that tissue engineered skin modulates aged dermal tissue to behave in a more sturdy fashion. Furthermore, in selected cases Apligraf may represent a treatment option for AP.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12472487     DOI: 10.1046/j.1524-4725.2002.02116.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  3 in total

1.  Engineered Vascularized Muscle Flap.

Authors:  Dana Egozi; Yulia Shandalov; Alina Freiman; Dekel Rosenfeld; David Ben-Shimol; Shulamit Levenberg
Journal:  J Vis Exp       Date:  2016-01-11       Impact factor: 1.355

2.  An engineered muscle flap for reconstruction of large soft tissue defects.

Authors:  Yulia Shandalov; Dana Egozi; Jacob Koffler; Dekel Dado-Rosenfeld; David Ben-Shimol; Alina Freiman; Erez Shor; Aviva Kabala; Shulamit Levenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-07       Impact factor: 11.205

Review 3.  A review of a bi-layered living cell treatment (Apligraf) in the treatment of venous leg ulcers and diabetic foot ulcers.

Authors:  Larissa Zaulyanov; Robert S Kirsner
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.